Skip to main content

A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS

Clinical Trial Grant
Duke Scholars

Administered By

Neurology

Awarded By

MediciNova, INC.

Start Date

March 26, 2020

End Date

December 31, 2024
 

Administered By

Neurology

Awarded By

MediciNova, INC.

Start Date

March 26, 2020

End Date

December 31, 2024